Roivant Sciences Ltd. (ROIV)
37.45
+0.65
(+1.77%)
USD |
NASDAQ |
Oct 22, 16:00
37.60
+0.15
(+0.40%)
After-Hours: 04:28
Roivant Sciences EPS Diluted (Quarterly) : -0.2634 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.2634 |
| March 31, 2026 | 0.373 |
| December 31, 2025 | -0.3816 |
| September 30, 2025 | -0.1667 |
| June 30, 2025 | -0.3283 |
| March 31, 2025 | -0.2919 |
| December 31, 2024 | 0.2344 |
| September 30, 2024 | -0.313 |
| June 30, 2024 | 0.1219 |
| March 31, 2024 | -0.1882 |
| December 31, 2023 | 6.035 |
| September 30, 2023 | -0.3951 |
| Date | Value |
|---|---|
| June 30, 2023 | -0.3843 |
| March 31, 2023 | -0.0453 |
| December 31, 2022 | -0.4935 |
| September 30, 2022 | -0.4166 |
| June 30, 2022 | -0.4768 |
| March 31, 2022 | -0.3899 |
| December 31, 2021 | -0.4144 |
| September 30, 2021 | -0.3206 |
| June 30, 2021 | -0.3701 |
| March 31, 2021 | -2.288 |
| March 31, 2020 | -0.2771 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Oxford Biomedica Plc | -- |
| Bicycle Therapeutics Plc | -0.7224 |
| Immunovant, Inc. | -0.7454 |
| Adaptimmune Therapeutics Plc | -0.1163 |
| Kiniksa Pharmaceuticals International Plc | 0.305 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -290.61M |
| Revenue (Quarterly) | 1.442M |
| Total Expenses (Quarterly) | 191.28M |
| Enterprise Value | 24.02B |
| Gross Profit Margin (Quarterly) | 38.70% |
| Profit Margin (Quarterly) | -20.15K% |
| Earnings Yield | -1.17% |
| Normalized Earnings Yield | -3.268 |